Published: November 10, 2010
Furiex Reports Third Quarter 2010 Financial Results
MORRISVILLE, N.C. - (BUSINESS WIRE) - Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial
and operating results for the quarter ended September 30, 2010. Furiex
was spun off from Pharmaceutical Product Development, Inc. (PPD) as a
separate public company effective June 14, 2010. As a result, the Furiex
financial information prior to that date was derived from PPD's
discovery sciences segment and does not reflect the consolidated results
of operations or cash flows of the company had it been a separate,
stand-alone entity.
Furiex recorded third quarter revenues of $0.3 million, compared to $0.4
million for the same period in the prior year. Revenue included
royalties related to Priligy sales in various countries outside the
United States and Nesina sales in Japan.
Research and development expenses were $20.0 million for the quarter,
compared to $0.3 million for the same period in the prior year. The
increase was primarily the result of development costs associated with
the two therapeutic compounds, MuDelta and JNJ-Q2, which Furiex
in-licensed from Janssen Pharmaceutica N.V. in November 2009. Furiex
issued a separate news release today announcing positive Phase II
clinical trial results for JNJ-Q2.
Third quarter selling, general and administration expenses were $1.5
million for the quarter compared to $0.3 million for the third quarter
of 2009. The increase was primarily the result of additional costs
associated with being a stand-alone publicly traded company.
Operating loss from continuing operations was $21.2 million, compared to
$0.2 million for the third quarter of 2009. The increase in loss from
continuing operations was predominantly a result of the increase in R&D
expense of $19.6 million.
Earnings (loss) per share for the third quarter of 2010 was $(2.14),
compared to $(0.58) for the third quarter of 2009. Third quarter 2009
earnings (loss) per share included PPD's loss from discontinued
operations, net of income taxes, of $(0.56) per share.
"We are extremely pleased with JNJ-Q2 results, which represent an
important milestone for the product and demonstrate its potential value
in the treatment of complicated skin infections," said June Almenoff,
M.D., Ph.D., president and chief medical officer of Furiex. "We are
confident that our expertise and strong balanced portfolio position us
well for future success."
Dr. Fred Eshelman, chairman of Furiex, added, "The rapid completion of
dosing JNJ-Q2 in the ABSSSI clinical trial confirms our proven ability
and long-time strategic vision to design and implement clinical
development programs more quickly and effectively to advance drugs
through Phase II, building value for our partners and Furiex."
Furiex will conduct a live conference call and webcast tomorrow,
November 11, 2010, at 9:00 a.m. ET to discuss its third quarter 2010
results, outlook for the full year, as well as an overview of our
business and pipeline. A Q&A session will follow. All interested parties
can access the webcast through the Presentations & Events link in the
Investors section of the Furiex website at www.furiex.com.
The webcast will be archived shortly after the call for on-demand
replay. The conference call will be broadcast live over the Internet and
will also be available using the following direct dial numbers:
|
Participant dial-in:
|
|
+1.877.267.0934 (U.S./Canada)
|
|
|
|
+1.706.643.0961 (International)
|
|
|
|
Conference ID:
|
|
16004351
|
About Furiex
Furiex Pharmaceuticals is a drug development collaboration company using
innovative clinical development design to accelerate and increase value
of partnered drug programs by advancing them through the drug discovery
and development process in a cost-efficient manner. Development programs
are designed and driven by a core team with extensive drug development
experience. The company collaborates with pharmaceutical and
biotechnology companies and has a strong, diversified product portfolio
and pipeline with multiple therapeutic candidates including clinical
stage assets and two products on the market. The company's mission is to
develop innovative medicines faster and at less cost, reducing the
expense of health care globally while providing life-improving therapies
for patients. For more information, visit www.furiex.com.
Except for historical information, all of the statements,
expectations and assumptions contained in this news release are
forward-looking statements that involve a number of risks and
uncertainties. Although Furiex attempts to be accurate in making these
forward-looking statements, it is possible that future circumstances
might differ from the assumptions on which such statements are based. In
addition, other important factors which could cause actual results to
differ materially include the following: the risks and expense of
continuing the research and development activities of our existing
candidates; progress of product candidates in clinical trials as it
relates to receiving future milestone payments; the ability of our
licensees to obtain regulatory approval and successfully manufacture and
market products licensed under our patents; the continued or additional
support by our collaborators or other third parties of R&D efforts and
clinical trials; time required to gain regulatory approvals; the demand
for our potential products, if and when approved; potential acquisitions
of technology, product candidates or businesses by us; and the costs of
defending or prosecuting any patent opposition or litigation necessary
to protect our proprietary technologies; and the other risk factors set
forth from time to time in the SEC filings for Furiex, copies of which
can be found on our website.
|
FURIEX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
Nine Months Ended
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
2010
|
|
|
|
2009
|
|
2010
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestones
|
|
|
|
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
$
|
5,000
|
|
$
|
7,500
|
|
|
Royalties
|
|
|
|
|
|
|
|
341
|
|
|
|
270
|
|
|
|
|
|
409
|
|
|
1,047
|
|
|
Service
|
|
|
|
|
|
|
|
101
|
|
|
|
-
|
|
|
|
|
|
357
|
|
|
75
|
|
|
Other
|
|
|
|
|
|
|
|
|
-
|
|
|
|
18
|
|
|
|
|
|
-
|
|
|
72
|
|
|
Total revenue
|
|
|
|
|
|
|
|
442
|
|
|
|
288
|
|
|
|
|
|
5,766
|
|
|
8,694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct expenses
|
|
|
|
|
|
|
|
60
|
|
|
|
-
|
|
|
|
|
|
247
|
|
|
21
|
|
|
Research and development expenses
|
|
|
|
|
|
349
|
|
|
|
19,993
|
|
|
|
|
|
1,924
|
|
|
40,227
|
|
|
Selling, general and administrative expenses
|
|
|
|
255
|
|
|
|
1,451
|
|
|
|
|
|
1,074
|
|
|
6,230
|
|
|
Depreciation and amortization
|
|
|
|
|
|
3
|
|
|
|
19
|
|
|
|
|
|
8
|
|
|
87
|
|
|
|
|
Total operating expenses
|
|
|
|
|
|
667
|
|
|
|
21,463
|
|
|
|
|
|
3,253
|
|
|
46,565
|
|
|
|
|
|
Operating income (loss)
|
|
|
|
|
|
(225
|
)
|
|
|
(21,175
|
)
|
|
|
|
|
2,513
|
|
|
(37,871
|
)
|
|
Other income
|
|
|
|
|
|
|
|
6
|
|
|
|
1
|
|
|
|
|
|
37
|
|
|
6
|
|
|
|
|
|
Income (loss) from continuing operations
before provision
for income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(219
|
)
|
|
|
(21,174
|
)
|
|
|
|
|
2,550
|
|
|
(37,865
|
)
|
|
Provision for income taxes
|
|
|
|
|
|
|
-
|
|
|
|
6
|
|
|
|
|
|
-
|
|
|
8
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
|
(219
|
)
|
|
|
(21,180
|
)
|
|
|
|
|
2,550
|
|
|
(37,873
|
)
|
|
Income (loss) from discontinued operations, net of income taxes
|
|
|
(5,477
|
)
|
|
|
-
|
|
|
|
|
|
23,904
|
|
|
(5,133
|
)
|
|
Net income (loss)
|
|
|
|
|
|
|
$
|
(5,696
|
)
|
|
$
|
(21,180
|
)
|
|
|
|
$
|
26,454
|
|
$
|
(43,006
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations per
basic and
diluted share
|
|
|
|
|
$
|
(0.02
|
)
|
|
$
|
(2.14
|
)
|
|
|
|
$
|
0.26
|
|
$
|
(3.83
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations,
net of income taxes per basic and diluted share
|
|
|
|
|
$
|
(0.56
|
)
|
|
$
|
-
|
|
|
|
|
$
|
2.42
|
|
$
|
(0.52
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per basic and diluted share
|
|
|
$
|
(0.58
|
)
|
|
$
|
(2.14
|
)
|
|
|
|
$
|
2.68
|
|
$
|
(4.35
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute net
income (loss) per basic and diluted share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,881
|
|
|
|
9,881
|
|
|
|
|
|
9,881
|
|
|
9,881
|
|
|
FURIEX PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
September 30,
|
|
|
|
|
|
|
|
|
|
2009
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
$
|
-
|
|
$
|
92,033
|
|
|
|
Accounts receivable and unbilled services
|
|
|
|
561
|
|
|
270
|
|
|
|
Prepaid expenses
|
|
|
|
|
|
41
|
|
|
352
|
|
|
|
Other current assets
|
|
|
|
|
|
3,464
|
|
|
72
|
|
|
|
Current assets of discontinued operations
|
|
|
|
1,969
|
|
|
-
|
|
|
|
|
Total current assets
|
|
|
|
|
|
6,035
|
|
|
92,727
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
|
|
|
-
|
|
|
198
|
|
|
Goodwill
|
|
|
|
|
|
|
49,116
|
|
|
49,116
|
|
|
Long-term assets of discontinued operations
|
|
|
|
726
|
|
|
-
|
|
|
|
|
Total assets
|
|
|
|
|
$
|
55,877
|
|
$
|
142,041
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders' Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
|
|
$
|
75
|
|
$
|
37
|
|
|
|
Accrued expenses
|
|
|
|
|
|
3,350
|
|
|
12,279
|
|
|
|
Current liabilities of discontinued operations
|
|
|
|
3,139
|
|
|
-
|
|
|
|
|
Total current liabilities
|
|
|
|
|
6,564
|
|
|
12,316
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities
|
|
|
|
|
|
-
|
|
|
186
|
|
|
Long-term liabilities of discontinued operations
|
|
|
|
43
|
|
|
-
|
|
|
|
|
Total liabilities
|
|
|
|
|
|
6,607
|
|
|
12,502
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value, authorized 40,000,000 shares;
|
|
|
|
|
9,881,340 shares issued and outstanding at September 30, 2010
|
|
-
|
|
|
10
|
|
|
Preferred stock, $0.001 par value, authorized 10,000,000 shares;
|
|
|
|
|
0 shares issued and outstanding at September 30, 2010
|
|
|
-
|
|
|
-
|
|
|
Paid-in capital
|
|
|
|
|
|
|
-
|
|
|
153,020
|
|
|
Pharmaceutical Product Development, Inc. net investment
|
|
|
49,270
|
|
|
-
|
|
|
Accumulated deficit
|
|
|
|
|
|
-
|
|
|
(23,491
|
)
|
|
|
|
Total shareholders' equity
|
|
|
|
|
49,270
|
|
|
129,539
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
|
$
|
55,877
|
|
$
|
142,041
|
|
Furiex Pharmaceuticals, Inc.
Media/Analysts/Investors:
Sailash
Patel, 919-456-7814
sailash.patel@furiex.com
Copyright © 2012, Business Wire, Inc., All rights reserved. Copyright © 2012, NewsBlaze, Daily News
|
Search News
